In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Featured article: Development of a rapid and specific MALDI-TOF mass spectrometric assay for SARS-CoV-2 detection
We have developed a MALDI-TOF mass spectrometric assay allowing a rapid, sensitive, robust and specific detection of SARS-CoV-2 infections in patient samples. Specifically, our approach enabled us to distinguish the SARS-CoV-2 delta variant from other viral variants and will be of potential use to detect other viral, bacterial and fungal infections.
Articles
-
-
Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex
-
Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables
-
Comparison of in-gel and in-solution proteolysis in the proteome profiling of organ perfusion solutions
-
A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes
-
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
-
Basics and recent advances of two dimensional- polyacrylamide gel electrophoresis
-
Nanotechnologies in Glycoproteomics
-
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research
-
Using phosphoproteomics data to understand cellular signaling: a comprehensive guide to bioinformatics resources
Archival content
Trezvuy - Fotolia
Have an idea for a new thematic series?
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Editor's profile
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Featured collections
Bioinformatic approaches for clinical proteomics: too many choices and no standardization
Guest edited by Ventzislava Hristova, Thang Pham, Bing Zhang
Spatial proteomics
Guest edited by Hui Zhang and Yuanwei Xu
Clinical translation of targeted proteomics
Guest edited by Tiannan Guo, Ed Nice, Stephen Pennington, Henry Rodriguez
Annual Journal Metrics
-
2022 Citation Impact
3.8 - 2-year Impact Factor
3.8 - 5-year Impact Factor
0.873 - SNIP (Source Normalized Impact per Paper)
0.941 - SJR (SCImago Journal Rank)2022 Speed
8 days submission to first editorial decision for all manuscripts (Median)
156 days submission to accept (Median)2022 Usage
309,920 downloads
315 Altmetric mentions